The effectiveness of photodynamic therapy (PDT) depends on the simultaneous presence in the tumor tissue of photosensitizer, oxygen and light. Factors restricting either of these parameters will limit PDT. One such limiting factor may be the existence of hypoxic tumor cell regions, which may be present prior to PDT due to poor tumor blood supply, or which may be created early during tumor illumination due to the severe vascular damage induced by PDT. Another possibly limiting factor is the development of hemorrhage accompanying PDT-induced vascular damage which may restrict light penetration before a fully effective light dose has been delivered to the tumor cells. It is proposed to examine the extent and significance of these limitations to PDT treatment in vivo. The oxygen dependency of PDT treatment will be determined at cellular prophyrin concentrations obtained under in vivo porphyrin uptake conditions. The possible influence of pre-existing hypoxic tumor cell regions on in vivo PDT will be examined. The effect of vascular PDT damage on tumor oxygenation and the possible creation of acutely hypoxic tumor areas during PDT light delivery will be studied. It will be examined if tumor reoxygenation occurs following PDT. The changes in light penetration through skin and tumor tissue during PDT will be monitored, and light loss due to hemorrhage will be measured. The possibility that enhancement of tumor oxygenation by oxygen-carrying chemicals and high oxygen breathing may enhance photodynamic tumor destruction will be studied.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA042278-01
Application #
3183339
Study Section
Radiation Study Section (RAD)
Project Start
1986-04-01
Project End
1989-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Seshadri, Mukund; Bellnier, David A; Vaughan, Lurine A et al. (2008) Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin Cancer Res 14:2796-805
Henderson, Barbara W; Busch, Theresa M; Snyder, John W (2006) Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med 38:489-93
Snyder, John W; Greco, William R; Bellnier, David A et al. (2003) Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res 63:8126-31
Henderson, B W; Busch, T M; Vaughan, L A et al. (2000) Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 60:525-9
Henderson, B W; Sitnik-Busch, T M; Vaughan, L A (1999) Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent. Photochem Photobiol 70:64-71
Sitnik, T M; Henderson, B W (1998) The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol 67:462-6
Sitnik, T M; Hampton, J A; Henderson, B W (1998) Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 77:1386-94
Henderson, B W; Vaughan, L; Bellnier, D A et al. (1995) Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol 62:780-9
Bellnier, D A; Henderson, B W; Pandey, R K et al. (1993) Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a. J Photochem Photobiol B 20:55-61
Mayhew, E; Vaughan, L; Panus, A et al. (1993) Lipid-associated methylpheophorbide-a (hexyl-ether) as a photodynamic agent in tumor-bearing mice. Photochem Photobiol 58:845-51

Showing the most recent 10 out of 20 publications